Clinical outcome of Brazilian patients with non-small cell lung cancer in early stage harboring rare mutations in epidermal growth factor receptor

Imagem de Miniatura
Arquivos
art_MACHADO-RUGOLO_Clinical_outcome_of_Brazilian_patients_with_nonsmall_cell_2022.PDF (301.01 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC BRAS DIVULG CIENTIFICA
Autores
OLIVIERI, E. H. R.
FABRO, A. T.
RAINHO, C. A.
CASTELLI, E. C.
RIBOLLA, P. E. M.
Citação
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.55, n.1, article ID e12409, 10p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The common epidermal growth factor receptor (EGFR) mutations, such as the L858R point mutation in exon 21 and the in-frame deletional mutation in exon 19, have been definitively associated with response to EGFR-tyrosine kinase inhibitors (EGFR-TKI). However, the clinical outcome and response to treatment for many other rarer mutations are still unclear. In this study, we report the results of Brazilian patients in stage IB-IIIA non-small cell lung cancer (NSCLC) following complete resection with minimal residual disease and EGFR mutations treated with adjuvant chemotherapy and/or EGFR-TKIs. The frequency of EGFR mutations was investigated in 70 cases of early stage NSCLC. Mutations in exons 18 and 20, uncommon mutations in exons 19 and 21, as well as in exons 3, 7, 14, 16, 22, 27, and 28, and/or the presence of different mutations in a single tumor (complex mutations) are considered rare. EGFR mutations were detected in 23 tumors (32.9%). Fourteen cases carried rare mutations and were treated with platinum-based chemotherapy and two cases were treated with erlotinib. The clinical outcome is described case by case with references to the literature. Notably, we found two rare EGFR mutations and one of them with an unknown response to chemotherapy and/or EGFR-TKIs. We have provided complementary information concerning the clinical outcome and treatment of patients with early stage NSCLC for several rare EGFR mutations not previously or only rarely reported. Description of cases harboring rare mutations can support the decision-making process in this subset of patients.
Palavras-chave
Lung cancer, Next generation sequencing, Rare EGFR mutation, Platinum-based chemotherapy, Erlotinib
URI
https://observatorio.fm.usp.br/handle/OPI/51472
Referências
  1. An ZY, 2018, ONCOGENE, V37, P1561, DOI 10.1038/s41388-017-0045-7
  2. Araujo LH, 2018, J BRAS PNEUMOL, V44, P55, DOI [10.1590/S1806-37562017000000135, 10.1590/s1806-37562017000000135]
  3. Arrieta O, 2015, LUNG CANCER, V87, P169, DOI 10.1016/j.lungcan.2014.12.009
  4. Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570
  5. Bi HH, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-6653
  6. Booth CM, 2012, J THORAC ONCOL, V7, P559, DOI 10.1097/JTO.0b013e31823f43af
  7. Chakroborty D, 2019, J BIOL CHEM, V294, P9377, DOI 10.1074/jbc.RA118.006336
  8. Chantharasamee J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5913-9
  9. Colby S, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a001230
  10. Dai LM, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013809
  11. De Pas T, 2011, J THORAC ONCOL, V6, P1895, DOI 10.1097/JTO.0b013e318227e8c6
  12. de Sa VK, 2016, LUNG CANCER-TARGETS, V7, P141, DOI 10.2147/LCTT.S93604
  13. Freitas HC, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01068
  14. Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313
  15. Han C, 2022, J CANCER RES CLIN, V148, P1265, DOI 10.1007/s00432-021-03864-4
  16. Hijiya N, 2008, HUM PATHOL, V39, P316, DOI 10.1016/j.humpath.2007.10.027
  17. Jackman DM, 2006, J CLIN ONCOL, V24, P4517, DOI 10.1200/JCO.2006.06.6126
  18. Jakobsen Jan Nyrop, 2018, Oncotarget, V9, P26195, DOI 10.18632/oncotarget.25490
  19. Machado-Rugolo J, 2021, PHARMACOGEN PERS MED, V14, P239, DOI 10.2147/PGPM.S286717
  20. Monteiro AS, 2022, J BRAS PNEUMOL, V48, DOI 10.36416/1806-3756/e20210283
  21. Moran T, 2020, CLIN LUNG CANCER, V21, P428, DOI 10.1016/j.cllc.2020.04.011
  22. Nicholson AG, 2022, J THORAC ONCOL, V17, P362, DOI 10.1016/j.jtho.2021.11.003
  23. Parra ER, 2020, ARCH PATHOL LAB MED, V144, P1234, DOI 10.5858/arpa.2019-0419-OA
  24. Rahman S, 2014, INT J CLIN ONCOL, V19, P45, DOI 10.1007/s10147-012-0515-4
  25. Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846
  26. Santamaria I, 2013, J CLIN ONCOL, V31, pE420, DOI 10.1200/JCO.2012.47.3512
  27. Sarcar B, 2019, FEBS OPEN BIO, V9, P1689, DOI 10.1002/2211-5463.12702
  28. Smits AJJ, 2012, CELL ONCOL, V35, P189, DOI 10.1007/s13402-012-0078-4
  29. Tam IYS, 2009, MOL CANCER THER, V8, P2142, DOI 10.1158/1535-7163.MCT-08-1219
  30. Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015
  31. Wong SQ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-23
  32. Zhang HJ, 2016, DRUG DES DEV THER, V10, P3867, DOI 10.2147/DDDT.S119162
  33. Zhang SS, 2022, LUNG CANCER-TARGETS, V13, P23, DOI 10.2147/LCTT.S358902

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/09
Carregar mais